Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Developing novel compounds to restore memory deficits in Alzheimer’s diseases
Memory loss associated with Alzheimer’s disease (AD) and other forms of dementia which affect over 800,000 people in the UK is an urgent social and economical challenge. So far development of drugs capable of ameliorating these diseases has been difficult and this problem needs to be tackled with committed focus. Evidence also suggests a preservation of the alpha5 containing GABAA receptors in human brain areas most affected by AD (Howell et al., 2000), which provide a strong rationale for developing potential therapeutic agents that would modulate the activity of alpha5 containing GABAA receptors. Based on the available structure, function information on these inverse agonists, we have developed novel hybrid molecules using medicinal chemistry. Using an interdisciplinary approach including, biomolecular stimulations provided by computational modelling combined with site-directed mutagenesis experiments, we aim to investigate the interaction of our novel compounds with alpah5 GABAA receptors. This project involves the following collaborators: Dr Stephen Hilton, Dr Shozeb Haider, Dr Jasmina Jovanovic (UCL School of Pharmacy); Dr Francesca Cacucci (Dept of Neuroscience, Physiology and Pharmacology, UCL).
1 Researchers
  • Pharmacology
 More search options
Status: Active
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by